TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17147908

Group type: EXPERIMENTAL
Intervention: Antiviral agents (specifically aciclovir)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiviral agents for post-exposure prophylaxis
Number of subjects: 0
Study: 15301652

Group type: EXPERIMENTAL
Intervention: Patients with delusions (no alternative explanation)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Patients with delusions (with alternative explanation)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patients with delusions (doubt in delusion, no alternative explanation)
Number of subjects: 100
Study: 11198059

Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 0
Study: 9062617

Group type: EXPERIMENTAL
Intervention: etomidate 0.3 mg kg‐1 for induction of anaesthesia
Number of subjects: 8

Group type: COMPARATOR
Intervention: thiopentone
Number of subjects: 8
Study: 8400493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at bedtime
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Allopurinol 50 mg 4 times daily
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: DMSO 500 mg 4 times daily
Number of subjects: 146
Study: 2956140

Group type: EXPERIMENTAL
Intervention: Rado-Salil ointment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29807669

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 65

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 65
Study: 27296091

Group type: EXPERIMENTAL
Intervention: Aspirin and omega-3 fatty acid supplements
Number of subjects: 423403

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 423403
Study: 24718930

Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 22639959

Group type: EXPERIMENTAL
Intervention: Tipifarnib plus low dose cytarabine (LDAC)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Low dose cytarabine (LDAC)
Number of subjects: 65
Study: 20437026

Group type: EXPERIMENTAL
Intervention: Baseline Central Retinal Arteriole Equivalent (CRAE)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Change in CRAE
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Change in Central Retinal Venule Equivalent (CRVE)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Baseline CRAE or CRVE or changes in these diameters
Number of subjects: 234
Study: 19153547

Group type: EXPERIMENTAL
Intervention: Vastus medialis muscle in children with lateral patellar instability
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 56
Study: 17024944

Group type: EXPERIMENTAL
Intervention: Single Bond (SB)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Additional layer of Single Bond (SB)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐purpose (SMP) adhesive applied over SB
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CE)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Additional layer of Clearfil SE Bond (CE)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Adper Prompt (AP)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Additional layer of Adper Prompt (AP)
Number of subjects: 35
Study: 15611806

Group type: EXPERIMENTAL
Intervention: Mucus clearance device (MCD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham mucus clearance device (SMCD)
Number of subjects: 15
Study: 10791110

Group type: EXPERIMENTAL
Intervention: ECP concentrations in nasopharyngeal secretions in asthmatic children
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: ECP concentrations in nasopharyngeal secretions in children with virus-induced wheezing
Number of subjects: 53

Group type: COMPARATOR
Intervention: ECP levels in serum among subjects
Number of subjects: 53
Study: 9069487

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8369232

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 900 mg to 1800 mg per day, stepwise increase over 12 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Orphenadrine 300 mg per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3465027

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 80
Study: 31187168

Group type: EXPERIMENTAL
Intervention: Nanoparticle albumin-bound paclitaxel (nab-ptx) used every week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Solvent-based paclitaxel used every week
Number of subjects: 0
Study: 27612310

Group type: EXPERIMENTAL
Intervention: Group intervention (1-hour sessions, 3-5 subjects, twice a week for 12 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Personal intervention (20-minute sessions, one staff member per participant, twice a week for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 26224825

Group type: EXPERIMENTAL
Intervention: Percutaneous Kirschner wire (K-wire) fixation
Number of subjects: 460

Group type: COMPARATOR
Intervention: Volar locking-plate fixation
Number of subjects: 460
Study: 24455059

Group type: EXPERIMENTAL
Intervention: 4% articaine (epinephrine 1:100,000)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0.5% bupivacaine (epinephrine 1:200,000)
Number of subjects: 36
Study: 20195788

Group type: EXPERIMENTAL
Intervention: Low-calorie carbohydrate-restricted diet (RD)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional low-calorie diet (CD)
Number of subjects: 19
Study: 19176895

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day for 6 weeks, then 10 mg/day for 42 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study: 17377162

Group type: EXPERIMENTAL
Intervention: Evaluation and treatment options for intermittent claudication, including potential revascularization.
Number of subjects: 1
Study: 15592331

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily for 3 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11380714

Group type: EXPERIMENTAL
Intervention: Amethocaine gel (topical application for 30 minutes)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo gel (topical application for 30 minutes)
Number of subjects: 40
Study: 9415510

Group type: EXPERIMENTAL
Intervention: Afferent A beta-fiber function (A beta-polyneuropathy)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Impairment of vibration sense (A beta-fiber function)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nociceptive C-fiber function
Number of subjects: 34

Group type: COMPARATOR
Intervention: Parasympathetic small fiber function
Number of subjects: 34

Group type: COMPARATOR
Intervention: Acute zoster pain intensity
Number of subjects: 34
Study: 8516087

Group type: EXPERIMENTAL
Intervention: Aerosol beclomethasone dipropionate (BDP), 84 micrograms four times a day
Number of subjects: 195

Group type: COMPARATOR
Intervention: Sustained‐release theophylline administered twice daily
Number of subjects: 195
Study: 3521784

Group type: EXPERIMENTAL
Intervention: Razoxane (postoperative, continuous, long-term)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control (identical clinical care, no adjuvant chemotherapy)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Razoxane
Number of subjects: 272
Study: 20604720

Group type: EXPERIMENTAL
Intervention: 30 mg urapidil
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 0.2 mg tamsulosin
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 50 mg naftopidil
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control therapy (240 mg flopropione and 1350 mg extract of Quercus salicina Blume/Quercus stenophylla Makino)
Number of subjects: 132
Study: 31948091

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/leucovorin and oxaliplatin ± bevacizumab
Number of subjects: 182
Study: 31109906

Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs prescribed in 157 (87%) participants, median of 1 (IQR 1-2) antihypertensive medication.
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Increasing number of antihypertensives.
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Adverse health events during follow-up.
Number of subjects: 181
Study: 28870194

Group type: EXPERIMENTAL
Intervention: EpiCor fermentate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 26308286

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (TA) injection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 50
Study: 23128450

Group type: EXPERIMENTAL
Intervention: 3 whole eggs per day (EGG)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Yolk-free egg substitute (SUB)
Number of subjects: 37
Study: 21736666

Group type: EXPERIMENTAL
Intervention: Fasting during Ramadan (≥10 fasting days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-fasting control group
Number of subjects: 72
Study: 19141433

Group type: EXPERIMENTAL
Intervention: Personalized SMS and MMS messages sent 2-5 times daily, printed materials, and brief monthly phone calls from a health counselor.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Monthly printed materials about weight control.
Number of subjects: 75
Study: 16785054

Group type: EXPERIMENTAL
Intervention: Protocol amendment
Number of subjects: 154

Group type: COMPARATOR
Intervention: Before protocol amendment
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: After protocol amendment
Number of subjects: 154
Study: 12871894

Group type: EXPERIMENTAL
Intervention: tibolone 2.5 mg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: tibolone 1.25 mg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: estradiol 2 mg plus norethisterone acetate 1 mg (E2 + NETA)
Number of subjects: 109
Study: 10960882

Group type: EXPERIMENTAL
Intervention: Zaleplon 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8793795

Group type: EXPERIMENTAL
Intervention: Fresenius Polysulfone membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyphen membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biosulfane membrane
Number of subjects: 0
Study: 1617039

Group type: EXPERIMENTAL
Intervention: Cefprozil
Number of subjects: 924

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 924

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 924

Group type: COMPARATOR
Intervention: Cefixime
Number of subjects: 924
Study: 6230950

Group type: EXPERIMENTAL
Intervention: Atracurium 0.2 mg/kg for muscle relaxation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 40
Study: 30375234

Group type: EXPERIMENTAL
Intervention: SUNBEAM programme (strength and balance exercise programme)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: SUNBEAM programme
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 221
Study: 29083530

Group type: EXPERIMENTAL
Intervention: 200 μg/mL amphotericin B nasal irrigation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Normal saline irrigation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Comparison between AMB and saline
Number of subjects: 73
Study: 26883281

Group type: EXPERIMENTAL
Intervention: Exercise training (experimental group)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Social/recreational activity (control group)
Number of subjects: 8
Study: 24657218

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 22196782

Group type: EXPERIMENTAL
Intervention: Postprocedural sustained VT/VF
Number of subjects: 3485

Group type: COMPARATOR
Intervention: Patients without postprocedural sustained VT/VF
Number of subjects: 3485
Study: 19763604

Group type: EXPERIMENTAL
Intervention: Clinical pathway (CP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no CP)
Number of subjects: 32
Study: 18619793

Group type: EXPERIMENTAL
Intervention: Registered mail
Number of subjects: 1550

Group type: COMPARATOR
Intervention: Normal post
Number of subjects: 1550
Study: 15675987

Group type: EXPERIMENTAL
Intervention: Continuous physostigmine infusion combined with morphine-based PCA
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCA alone
Number of subjects: 0
Study: 12166337

Group type: EXPERIMENTAL
Intervention: 0.3 mg ramosetron intravenously
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 10381905

Group type: EXPERIMENTAL
Intervention: 10 mg aspirin daily for 3 months
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 81 mg aspirin daily for 3 months
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 325 mg aspirin daily for 3 months
Number of subjects: 29
Study: 8547651

Group type: EXPERIMENTAL
Intervention: High bcl-2 expression (found in 131 patients, 45%)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Negative/intermediate bcl-2 expression (94 patients, 32% negative and 94 patients with intermediate staining)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: High bcl-2 expression in diffuse large B-cell lymphoma (67 patients, 44%)
Number of subjects: 290
Study: 1844773

Group type: EXPERIMENTAL
Intervention: Cefuroxime (250 mg td) for 7 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Trimethoprim sulfamethoxazole (160/800 mg td) for 7 days
Number of subjects: 40
Study: 6557966

Group type: EXPERIMENTAL
Intervention: 5 mg Fenoterol orally before 0.4 mg PGE2 gel
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 0.4 mg PGE2 gel
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 0.8 mg PGE2 gel
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 26
Study: 30972702

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 361

Group type: COMPARATOR
Intervention: Investigator's Choice (IC)
Number of subjects: 361
Study: 29164902

Group type: EXPERIMENTAL
Intervention: Protocolised clinical intervention plus usual care (n = 64)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Usual care alone (n = 63)
Number of subjects: 127
Study: 26762497

Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate with Opsite (G+O)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate with Tegaderm (G+T)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Opsite without 2-octyl cyanoacrylate (O)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Overall comparison across all groups
Number of subjects: 211
Study: 24622803

Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 737

Group type: COMPARATOR
Intervention: Low-protein diet
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Weight regain from 6 to 24 months
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Protein intakes
Number of subjects: 737
Study: 21415284

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1200 mg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 2400 mg
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (single dose)
Number of subjects: 67
Study: 19328257

Group type: EXPERIMENTAL
Intervention: Underreporting detection methods
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Weight status (overweight and obese)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Anglo orientation score
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Age group of 51 years or older
Number of subjects: 357
Study: 17993728

Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard enteral nutrition
Number of subjects: 41
Study: 15379365

Group type: EXPERIMENTAL
Intervention: EE/DRSP (30 microg ethinyl estradiol and 3 mg drospirenone)
Number of subjects: 1154

Group type: COMPARATOR
Intervention: EE/NGM (35 microg ethinyl estradiol and 0.180, 0.215, 0.250 mg norgestimate)
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 1154
Study: 11307411

Group type: EXPERIMENTAL
Intervention: Laser-assisted therapy (diode laser light, 1-watt output, maximum of 20 seconds)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 50
Study: 9381042

Group type: EXPERIMENTAL
Intervention: Gabapentin monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 0
Study: 8398517

Group type: EXPERIMENTAL
Intervention: Amethocaine patch (30-min application)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amethocaine patch (60-min application)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EMLA (60-min application)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amethocaine gel preparation
Number of subjects: 0
Study: 3943382

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO) at 3 Hz, maximal pressure (90 to 102 cm H2O)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO) at 3 Hz, half-maximal pressure
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO) at 5 Hz, maximal pressure
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO) at 5 Hz, half-maximal pressure
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO) at 8 Hz, maximal pressure
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO) at 8 Hz, half-maximal pressure
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO) at 3 Hz, maximal pressure
Number of subjects: 5
Study: 3338251

Group type: EXPERIMENTAL
Intervention: Rebreathing a 2% CO mixture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breath-hold CO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean alveolar CO
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breath-hold and rebreathing CO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breath-hold and mean alveolar CO
Number of subjects: 0
Study: 31218964

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.9% normal saline (placebo)
Number of subjects: 80
Study: 28728744

Group type: EXPERIMENTAL
Intervention: Beta Blocker (BB) use at ≥50% target dose
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Increase in heart rate (HR) by 10 beats/min
Number of subjects: 129
Study: 25789519

Group type: EXPERIMENTAL
Intervention: Estrogen therapy (2.0 mg of 17β‐estradiol)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Estrogen‐progestin therapy (2.0 mg of 17 β‐estradiol + 1.0 mg of norethisterone acetate)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 99
Study: 23743559

Group type: EXPERIMENTAL
Intervention: Pegylated-interferon (IFN) α‐2b plus ribavirin for 16 weeks
Number of subjects: 130

Group type: COMPARATOR
Intervention: Pegylated-interferon (IFN) α‐2b plus ribavirin for 24 weeks
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Cost analysis for 16 weeks treatment
Number of subjects: 130

Group type: COMPARATOR
Intervention: Cost analysis for 24 weeks treatment
Number of subjects: 130
Study: 21930798

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 792
Study: 19451304

Group type: EXPERIMENTAL
Intervention: KBPA-101 at 0.1 mg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: KBPA-101 at 0.4 mg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: KBPA-101 at 1.2 mg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: KBPA-101 at 4.0 mg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: KBPA-101
Number of subjects: 32
Study: 16549451

Group type: EXPERIMENTAL
Intervention: 5 mg of labeled zinc (67Zn) with 50 mg AA (LoZn group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 10 mg of labeled zinc (67Zn) with 50 mg AA (HiZn group)
Number of subjects: 75

Group type: COMPARATOR
Intervention: 5 mg zinc with no AA (control)
Number of subjects: 75
Study: 15286543

Group type: EXPERIMENTAL
Intervention: Once-daily dosing (ODD) of tobramycin (7 mg/kg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Multiple daily dosing (MDD) of tobramycin
Number of subjects: 58
Study: 11130626

Group type: EXPERIMENTAL
Intervention: Smoking intervention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 9331215

Group type: EXPERIMENTAL
Intervention: Latanoprost 15 microg/ml twice daily
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Latanoprost 50 microg/ml once daily
Number of subjects: 50
Study: 8226140

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy to doses of 60.0 Gy, 64.8 Gy, 69.6 Gy, 74.4 Gy, or 79.2 Gy, 1.2 Gy twice daily, 5 days per week.
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy with deviations in treatment time.
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Standard fractionation (55-60 Gy in 30 fractions).
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Hyperfractionation (69.6 Gy or higher).
Number of subjects: 1244
Study: 2418902

Group type: EXPERIMENTAL
Intervention: Permixon (160 mg bd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31679465

Group type: EXPERIMENTAL
Intervention: 8-week low-energy diet before total knee replacement
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 76
Study: 29596150

Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (24 international units)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 27
Study: 25497998

Group type: EXPERIMENTAL
Intervention: EPG 10 g/day
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: EPG 25 g/day
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: EPG 40 g/day
Number of subjects: 139

Group type: COMPARATOR
Intervention: Margarine alone (control)
Number of subjects: 139
Study: 21347608

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (gel)
Number of subjects: 38